Rituxan

JHL's Judas Kiss: an Inside Look at JHL Biotech's Theft from Genentech
BioSpace
Fri, 03/18/22 - 10:44 am
JHL Biotech
Genentech
Roche
trade secrets
Rituxan
Samsung Biologics, AstraZeneca to dissolve biosimilar JV, scrap Rituxan copy program: report
Fierce Pharma
Thu, 11/19/20 - 08:29 pm
Samsung BioLogics
AstraZeneca
Rituxan
Roche
biosimilars
Archigen Biotech
10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says
BioSpace
Mon, 03/9/20 - 11:10 pm
biosimilars
Amgen
Allergan
Roche
Rituxan
Bristol-Myers Squibb
ozanimod
risdiplam
Biomarin
valrox
Pfizer launches biosimilars to Roche’s ‘big three’ cancer drugs in US
Pharmaforum
Fri, 01/24/20 - 10:11 am
Pfizer
Roche
biosimilars
Avastin
Zirabev
Herceptin
Trazimera
Rituxan
Ruxience
New MS Trial Will be First to Compare Stem Cell Therapy with Best Available Biologics
Xtalks
Mon, 01/13/20 - 11:35 pm
stem cells
MS
multiple sclerosis
NIH
AHSCT
Biogen
Tysabri
Sanofi
Lemtrada
Roche
Ocrevus
Rituxan
Amgen, Allergan join Rituxan biosimilar challenge with FDA filing
Pharmaforum
Fri, 12/20/19 - 12:15 pm
Amgen
Allergan
biosimilar
Roche
Rituxan
Say hello to Roche's worst-case scenario: Teva's Rituxan biosim set to launch in U.S.
Fierce Pharma
Thu, 11/7/19 - 11:05 am
Roche
Teva Pharmaceutical
Celltrion
Rituxan
biosimilars
MabThera
Truxima
Humira, Rituxan top list of U.S. drugs with biggest price increases -report
Yahoo/Reuters
Tue, 10/8/19 - 09:23 am
ICER
drug pricing
AbbVie
Humira
Roche
Rituxan
Roche gets FDA nod for Rituxan to treat children with two blood vessel disorders
Pharmaceutical Business Review
Mon, 09/30/19 - 12:09 pm
Roche
FDA
Rituxan
eosinophilic granulomatosis with polyangiitis
microscopic polyangiitis
Amgen, Allergan biosimilar of Roche's blockbuster Rituxan clears another US pivotal study
Endpoints
Thu, 08/22/19 - 11:54 am
Novartis
Amgen
Allergan
biosimilars
Roches
Rituxan
ABP 798
Roche clinches EU approval for MabThera in rare autoimmune indication — will it boost dwindling sales amid biosimiar competition?
Endpoints
Fri, 03/15/19 - 09:30 am
Roche
MabThera
Rituxan
Europe
biosimilars
Top 10 drugs losing exclusivity in 2019
Fierce Pharma
Tue, 03/5/19 - 09:40 am
market exclusivity
patents
Rituxan
Lyrica
Herceptin
Avastin
Epclusa
Harvoni
Pfizer
Roche
Gilead Sciences
Amgen
GSK
Allergan
Individor
Celgene gets fast FDA review of Revlimid combo in lymphoma
Pharmaforum
Wed, 02/27/19 - 10:49 am
Celgene
Revlimid
FDA
Roche
Rituxan
priority review
Novartis' Sandoz calls it quits on Rituxan biosimilar after FDA requests more data
Fierce Pharma
Mon, 11/5/18 - 11:53 am
Novartis
Sandoz
FDA
biosimilars
Roche
Rituxan
Celgene lines up for $600M Revlimid boost as Rituxan combo scores in lymphoma
Fierce Pharma
Sat, 11/3/18 - 04:05 pm
Celgene
Revlimid
Roche
Rituxan
follicular lymphoma
FDA panel unanimously backs Celltrion's Rituxan biosimilar
Fierce Pharma
Wed, 10/10/18 - 10:57 pm
Celltrion
Teva Pharmaceutical
biosimilars
Rituxan
FDA
advisory panels
FDA reviewers endorse Celltrion's Rituxan biosimilar ahead of panel vote
Fierce Pharma
Tue, 10/9/18 - 12:01 pm
Celltrion
Roche
biosimilars
Rituxan
FDA
advisory panels
Jumping ahead of AstraZeneca, AbbVie and J&J get a green light to market Imbruvica/Rituxan combo for rare lymphoma
Endpoints
Mon, 08/27/18 - 10:02 am
AbbVie
JNJ
FDA
Imbruvica
Rituxan
Roche
AstraZeneca
non-Hodgkin's lymphoma
Waldenström’s macroglobulinemia
Can Celgene's latest Revlimid win reverse the company's bad-news streak?
Fierce Pharma
Tue, 07/24/18 - 06:00 pm
Celgene
Revlimid
clinical trials
Roche
Rituxan
non-Hodgkin lymphoma
AbbVie, Roche post a big win with a blockbuster FDA OK for Venclexta/Rituxan combo for leukemia
Endpoints
Mon, 06/11/18 - 09:17 am
AbbVie
Roche
Venclexta
Rituxan
CLL
chronic lymphocytic leukemia

Pages